Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Cahill, C. Costello, K. Howell, M. Leonard, M. Southwood, N.W. Morrell, P. McLoughlin (Dublin, Ireland). Oral presentation: The bone morphogenetic protein antagonist Gremlin in pulmonary hypertension. Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis

Member's Comments

No comment yet.

Related content which might interest you: Dysregulated bone morphogenetic protein signaling in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Source: Eur Respir J 2009; 34: 1100-1110 Year: 2009 Pulmonary vascular disease: an historical perspective Source: Eur Respir Mon 2012; 57: 1-16 Year: 2012 Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The adverse effect of estrogen on bone morphogenetic protein receptor (BMPR) signal pathway in pulmonary arterial endothelial cells (PAEC) Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003 Pathobiology of pulmonary arterial hypertension and right ventricular failure Source: Eur Respir J 2012; 40: 1555-1565 Year: 2012 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Bone morphogenetic protein receptor-II as a regulator of pulmonary artery endothelial cell permeability: Relevance to the initiation and progression of heritable pulmonary arterial hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 The microRNA cluster 17/92 regulates the expression of the bone morphogenetic protein receptor type II involved in the pathogenesis of pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Role of Gremlin in pulmonary hypertension Source: Annual Congress 2012 - Contributing factors to pulmonary hypertension Year: 2012 BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Source: Eur Respir J 2002; 20: 518-523 Year: 2002 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Implication of bone marrow-derived c-kit positive cells in idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Oral presentation: Increased CXCR4 expression and short telomeres in bone marrow mesenchymal stem cells of patients with idiopathic pulmonary fibrosis Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Bone morphogenetic proteins (BMPs) inhibit hypoxia stimulated human pulmonary artery fibroblast (PAF) proliferation via inhibition of p38 MAP kinase and HIF-1α Source: Annual Congress 2004 - Pathophysiology of pulmonary hypertension Year: 2004